Last: | $0.89 |
---|---|
Change Percent: | -2.82% |
Open: | $0.95 |
Close: | $0.89 |
High: | $0.959999 |
Low: | $0.86 |
Volume: | 366,297 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.89 | $0.95 | $0.89 | $0.959999 | $0.86 | 366,297 | 07-02-2024 |
$0.9239 | $0.9291 | $0.9239 | $0.9599 | $0.897 | 123,322 | 07-01-2024 |
$0.9475 | $0.95 | $0.9475 | $0.96 | $0.89 | 139,796 | 06-28-2024 |
$0.94 | $0.89 | $0.94 | $0.9699 | $0.89 | 47,187 | 06-27-2024 |
$0.9121 | $0.949799 | $0.9121 | $0.949799 | $0.904 | 54,772 | 06-26-2024 |
$0.9001 | $0.95 | $0.9001 | $0.9501 | $0.9001 | 183,109 | 06-25-2024 |
$0.9308 | $0.9 | $0.9308 | $0.9525 | $0.8605 | 66,214 | 06-24-2024 |
$0.9084 | $0.9401 | $0.9084 | $0.9401 | $0.852222 | 476,685 | 06-21-2024 |
$0.9536 | $0.95 | $0.9536 | $1.02 | $0.930101 | 85,270 | 06-20-2024 |
$0.9469 | $0.95 | $0.9469 | $0.9926 | $0.94 | 96,975 | 06-19-2024 |
$0.9469 | $0.95 | $0.9469 | $0.9926 | $0.94 | 96,975 | 06-18-2024 |
$0.95 | $1.02 | $0.95 | $1.02 | $0.94 | 199,360 | 06-17-2024 |
$1.02 | $1.02 | $1.02 | $1.05 | $1.02 | 45,660 | 06-14-2024 |
$1.05 | $1.08 | $1.05 | $1.08 | $1.01 | 118,670 | 06-13-2024 |
$1.06 | $1.13 | $1.06 | $1.14 | $1.05 | 143,981 | 06-12-2024 |
$1.12 | $1.09 | $1.12 | $1.13 | $1.05 | 113,232 | 06-11-2024 |
$1.06 | $1.04 | $1.06 | $1.125 | $1.04 | 154,359 | 06-10-2024 |
$1.05 | $1.04 | $1.05 | $1.06 | $0.98 | 7,175,939 | 06-07-2024 |
$1.02 | $1.01 | $1.02 | $1.0699 | $1 | 103,113 | 06-06-2024 |
$1.02 | $1.04 | $1.02 | $1.07 | $0.9802 | 169,160 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Xilio Therapeutics Inc. Company Name:
XLO Stock Symbol:
NASDAQ Market:
Xilio Therapeutics Inc. Website:
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Sh...
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-a...